Aquestive Therapeutics, Inc. AQST Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s cash & equivalents?
- Aquestive Therapeutics, Inc. (AQST) reported cash & equivalents of $110.73M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Aquestive Therapeutics, Inc.'s cash & equivalents increased by 61.3% year-over-year, from $68.66M to $110.73M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s cash & equivalents has grown at a 30.7% compound annual growth rate (CAGR), from $31.81M to $121.17M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.